Name
Address/P.O. Box Postal Code/City Country Contact Person Telephone Email Website Social Media Number of Employees Founded (year) Type of Laboratory Areas of Activity
Request for Further Collaborations
›
YUMAB GmbH Science Campus Braunschweig-Süd
›
Inhoffenstr. 7 38124 Braunschweig Germany Alexander Ehm +49-531-481170-0 info@yumab.com www.yumab.com
›
IQ
› › › › › ›
› › ›
›
›
27 2012 S1, S2 | Fully human antibody discovery & lead development | Antibody Libraries | Engineering & Humanisation | Professional R&D services (CRO) | Optimised conditions for start-up, biotech & biopharma companies | Flexible entry & exit points at any project stage | Partnered innovation YUMAB seeks clients & partners in biopharma, biotech & diagnostic industry as well as partners with innovative research projects, who need a reliable partner in human antibody development
YUMAB is a contract developer of fully human antibodies for the global biotechnological and biopharmaceutical industry. Starting in 2012 with the goal to bridge the gap between innovative research and novel therapies, the company has become an important driver of the general trend in immunotherapy toward the use of fully human antibodies. The versatile technology platform combined with a longstanding and proven expertise makes YUMAB the partner of choice for the development of novel antibodies for therapeutic applications, diagnostics, or vaccines tailored to the clients’ needs. R&D projects customised with flexible entry and exit points at any stage and for any immunotherapeutic strategy appeal to start-ups, biotech, or biopharma companies. With the starting pandemic early 2020, YUMAB collaborated with the University Braunschweig and other partners to develop antibodies against SARS-CoV-2. The promising results ended in the YUMAB spin-out CORAT Therapeutics GmbH (see seperate company profile on page 68 ), founded in May 2020. The collaboration and its success were honored with the Innovation Award of the state of Lower Saxony at the end of September 2020. Currently, the antibody drug candidate COR-101 is in the clinical phase Ib/II, which is being conducted at five study centers in Germany. Here, COR-101 is being tested in hospitalized patients, in particular to assess safety, tolerability, and efficacy.
The YUMAB® platform: fast & reliable translation from innovation to drugs The YUMAB® R&D platform delivers fully human antibodies, the closest to natural germline among those on the market, using fast and reliable in vitro discovery technologies. The company’s highly diverse, human antibody libraries contain 1011 natural antibody sequences and specificities to all types of antigens. Unlike animalderived, chimeric, humanised, or synthetic antibodies, each YUMAB® antibody sequence has been shaped in the human body, which maximises epitope diversity and overcomes restriction by in vivo immune responses while minimising immunogenicity and potential adverse effects in clinical development.
